Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084786 · ClinicalTrials.gov registry record · Phase 1
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00084786: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00084786 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084786, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die. Giving gefitinib with docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gefitinib when given with docetaxel in treating patients with advanced solid tumors.
Interventions
- DRUG docetaxel
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00084786 record still lists
NCT00084786 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00084786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084786 about?
NCT00084786 is a clinical study titled "Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die. Giving gefitinib with docetaxel may kill more tumor cells. P...
What is the current status of trial NCT00084786?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-03.
What interventions are being tested in trial NCT00084786?
The interventions under investigation include: docetaxel (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00084786?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia